Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

RecruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

May 21, 2022

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

TUKYSA®

tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.

Trial Locations (2)

NOT_YET_RECRUITING

Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie, Vienna

RECRUITING

Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen

All Listed Sponsors

collaborator

Seagen Inc.

INDUSTRY

lead

iOMEDICO AG

INDUSTRY